The success of GLP-1 receptor agonists, first for diabetes and then expanded to obesity and CVD, laid crucial groundwork for the widespread adoption of multi-indication clinical development. Learn more in our article. ow.ly/tCQw50WvY09

Keep your knowledge of the latest clinical trial regulatory authority updates current, by subscribing to our free newsletter. ow.ly/l65e50WwH5F

For #NIAM2025 we look at the recent history and the future of vaccine development and assess the important role of long-term follow up (LTFU) to demonstrate vaccine efficacy and safety. Learn why LTFU should start early on in trials. ow.ly/J0Qr50WBlGS

How should you launch a multi-indication therapy? Developers face a key strategic question: choose a "narrow first" approach for premium pricing, or a "broad first" strategy for early market share? Our article explores the distinct trade-offs of each. ow.ly/LIf750WBo8P

Real-world data. Real patient impact. For #PsoriasisAwarenessMonth, discover how Symphony Health, an ICON plc company, helped a brand navigate free drug programs, prescriber behaviour & market expansion with RWE. Learn more: ow.ly/4IE050Wc5RX

AI in medical devices is booming—over 1,000 FDA approvals and counting. But are global regulations ready? New from ICON experts in Med-Tech Insights: How developers can navigate evolving expectations for AI-enabled SaMD. ow.ly/TjCK50WF7xf #MedTech #AI #SaMD #FDA

Submitting #clinicaldata to both the #FDA and #PMDA can be complex. Our whitepaper shows how to simplify the process and reduce duplication. Read the whitepaper for expert insights: ow.ly/wUkp50WHEc2

From complexity to clarity. See how ICON’s blended delivery model provides flexible, scalable solutions to suit or partners’ evolving clinical needs. Explore real results in our blended solutions case studies: ow.ly/sYI750WxhRV

Pharma literature is exploding - SLRs help you make sense of it all. New whitepaper: “Demystifying the systematic literature review” - When & how to use SLRs - Avoid common pitfalls - Boost evidence quality Download here: ow.ly/2LsT50WHo4q #Pharma #SLR #MedicalAffairs #HEOR

How do cold urticaria patients define meaningful change? New study uses exit interviews to validate PROs - highlighting the power of patient voice in clinical research. ow.ly/CRb950WFRGB #ClinicalTrials #ColdUrticaria #PROs #PatientExperience

Medical writing teams play a central role in regulatory submissions, but success depends on more than writing skill alone. In this IBI article, our experts explore how planning and collaboration support high quality, timely submissions. Read more: ow.ly/yh4V50WxcsE

When commercialising a multi-indication drug, a narrow first launch strategy targets high-value populations for premium pricing but may slow accumulation of real world evidence. Understand these trade-offs in our article. ow.ly/8Ptm50WBo9Q

In a few days at #SCDM 2025 South Africa in Bloemfontein, ICON will lead talks on clinical data excellence—governance, secure access, digital innovation & regulatory impacts on data management. Details: ow.ly/PuwY50WEmlz

The UK offers an alternative path if the EU’s joint scientific consultation (JSC) process is not meeting your trial timelines. Learn more in our latest UK series blog ow.ly/SybG50WIHhs

Antibody-drug conjugates (ADCs) represent a growing class of targeted therapies, but their pharmacokinetic assessment presents unique challenges due to structural complexity, multiple analytes, and the need for diverse assay types. Read more: ow.ly/AOv650WvV9o

The ICH GCP E6(R3) update is here and it’s a game changer. Discover how RBQM is reshaping trial oversight with smarter, risk-proportionate strategies. ow.ly/28x550WIHW5 #RBQM #ClinicalTrials #GCP #Biotech #Pharma

In the fast-paced world of pharma, making informed decisions starts with understanding the evidence. Our new whitepaper, “Demystifying the SLR: ‘S’ Stands for Systematic,” breaks down how Systematic literature reviews can help you. Download your copy: ow.ly/ouNv50WIIiu

Why are 700+ AI medical devices in radiology—but only 30 in neurology? Our new article in Med-Tech Insights breaks down the regulatory and technical reasons behind the imbalance. ow.ly/Yxjy50WF7Ew #MedTech #AI #FDA #SaMD #HealthcareInnovation

Antibody-Drug Conjugates (ADCs) combine potent cytotoxins with selective antibodies for targeted cancer therapy. As ADC development rapidly evolves, so must our bioanalytical strategies. Discover key insights and solutions to support ADC drug development. ow.ly/KyBJ50Wp0zc

ICON is pleased to join industry leaders at #DPHARM2025 this 16 - 17 September. Connect with our experts at booth #305 and see how our clinical, consulting, and commercial solutions accelerate innovation and improve patient outcomes. ow.ly/7ak950WJwmn